Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.25), $0.15 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $133.2 million versus the consensus estimate of $135.42 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.